RxDoctor Payments Data

Judy Mitchelson, PA

Physician Assistant · Galesburg, MINPI 1801900121

Payments from drug & device makers

$923in general payments, 2019–2025

Across 31 payments — averaging $29.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$214
  • AstraZeneca$179
  • Abbott$172
  • Boehringer Ingelheim$123
  • Pfizer$78
  • AbbVie$46
  • plus $112 from 6 others

What the payments were for

  • Food & beverage$923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$923 in reported general payments places this provider in the 70th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$27,020
Medicare patients
151
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$69,455
TrulicityDulaglutide55$67,419
EliquisApixaban63$46,843
RybelsusSemaglutide18$31,799
MounjaroTirzepatide21$29,238
JardianceEmpagliflozin28$28,701
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$27,120
XareltoRivaroxaban24$26,051
FarxigaDapagliflozin Propanediol29$25,671
MyrbetriqMirabegron18$11,366
Spiriva RespimatTiotropium Bromide18$10,118
TrintellixVortioxetine Hydrobromide13$8,289
MotegrityPrucalopride Succinate13$7,468
LinzessLinaclotide13$6,371
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$214$101,25481 claims
Lilly USA, LLCTrulicity, Mounjaro$16$96,65876 claims
PfizerEliquis$78$46,84363 claims
Boehringer IngelheimJardiance, Spiriva Respimat$123$38,81946 claims
AstraZenecaFarxiga, Bevespi Aerosphere$179$30,55441 claims
Astellas Pharma US IncMyrbetriq$25$11,36618 claims
AbbVieLinzess$46$6,37113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Galesburg

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →